Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone acetate
Drug ID BADD_D01434
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D00979
MeSH ID D000077555
PubChem ID 5877
TTD Drug ID Not Available
NDC Product Code 0009-0026; 10695-041; 38779-0144; 46439-8767; 82298-117; 0009-0274; 50090-6024; 60219-1574; 0009-0306; 68788-8082; 76420-262; 0781-3516; 51552-0958; 0009-3073; 76420-260; 25021-821; 0009-0280; 50090-0436; 49452-4688; 71052-161; 25021-820; 70121-1552; 76420-081; 60722-1007; 0009-3475; 55150-313; 63187-474; 70121-1573; 70121-1574; 52128-148; 42023-239; 42023-240; 55150-314; 51927-0000; 63275-9942; 65089-0016; 50090-0556; 51662-1429; 22552-0023; 50090-5894; 60219-1573
UNII 43502P7F0P
Synonyms Methylprednisolone Acetate | Methylprednisolone-21-acetate | Methylprednisolone 21 acetate | Acetyl-Methylprednisolone | Acetyl Methylprednisolone | Depo-Medrone | Depo Medrone | Depo-Medrol | Depo Medrol | Methylprednisolone Acetate, (11beta,16beta)-isomer | Methylprednisolone Acetate, (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C24H32O6
CAS Registry Number 53-36-1
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Secondary adrenocortical insufficiency14.11.01.014; 05.03.04.012--Not Available
Seizure17.12.03.001--
Sensory disturbance17.02.07.006--Not Available
Skin atrophy23.01.05.001--
Skin disorder23.03.03.007--Not Available
Skin hyperpigmentation23.05.01.003--
Skin hypopigmentation23.05.02.003--
Skin striae23.01.05.002--Not Available
Small intestinal perforation07.04.06.006--
Sodium retention14.05.04.003--Not Available
Spermatozoa progressive motility abnormal13.20.04.011--Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.001--Not Available
Steroid withdrawal syndrome05.01.02.007; 19.04.02.014; 08.06.02.013--Not Available
Suicidal ideation19.12.01.003--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Telangiectasia23.06.03.001; 24.03.03.003--
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Thrombophlebitis24.01.02.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis10.02.02.006; 24.12.04.027--
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.013--Not Available
Weight increased13.15.01.006--
Oesophagitis ulcerative07.04.05.003--Not Available
Urine calcium increased13.11.01.039--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.007--
Affect lability19.04.01.001--Not Available
Scleral thinning06.09.06.004--Not Available
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages